Neuphoria Therapeutics (NEUP) EPS (Weighted Average and Diluted) (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported EPS (Weighted Average and Diluted) of -$0.09 for Q1 2026, down 101.37% year-over-year from $6.55 in Q1 2025, and up 88.31% on a QoQ basis from -$0.77 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.09 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 101.37% year-over-year to -$0.09 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.06 (down 1636.11% YoY) and the FY2025 annual result came in at -$0.23, up 98.76% from the prior year.
- EPS (Weighted Average and Diluted) advanced to -$0.09 in Q1 2026 per NEUP's latest filing, from -$0.77 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $6.55 in Q1 2025 and bottomed at -$5.79 in Q2 2025.
- The 4-year median for EPS (Weighted Average and Diluted) is -$1.79 (2024), against an average of -$1.68.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) slumped 16848.48%; it then jumped 331.45% in 2025.
- Tracing NEUP's EPS (Weighted Average and Diluted) over 4 years: stood at -$5.31 in 2023, then soared by 66.29% to -$1.79 in 2024, then surged by 56.98% to -$0.77 in 2025, then soared by 88.31% to -$0.09 in 2026.
- Per Business Quant, the three latest NEUP EPS (Weighted Average and Diluted) figures stand at -$0.09 (Q1 2026), -$0.77 (Q4 2025), and -$4.41 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -0.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.09 |
| Dec 31, 2025 | -0.77 |
| Sep 30, 2025 | -4.41 |
| Jun 30, 2025 | -3.98 |
| Mar 31, 2025 | 6.55 |
| Dec 31, 2024 | -1.79 |
| Sep 30, 2024 | -0.62 |
| Jun 30, 2024 | -3.42 |
| Mar 31, 2024 | -2.83 |
| Dec 31, 2023 | -5.31 |
| Sep 30, 2023 | 0.00 |